Darbà, JosepAscanio, Meritxell2020-05-292020-05-2920190172-780Xhttps://hdl.handle.net/2445/163049In Spain it is necessary to conduct additional studies to determine place in therapy and cost-effectiveness of a drug. The main objective of this study is to identify all drug assessments and health technology assessment reports of the drugs for gastroenteropancreatic (GEP) neuroendocrine tumors (NET) at a national, regional and hospital level and to summarize the efficacy in terms of outcome measures, adverse events, economic impact and final recommendations.7 p.application/pdfengcc-by-nc-nd (c) Maghira & Maas , 2019http://creativecommons.org/licenses/by-nc-nd/3.0/esEndocrinologiaNeurologiaTumorsEndocrinologyNeurologyTumorsinfo:eu-repo/semantics/article6911142020-05-29info:eu-repo/semantics/openAccess